ArticleEuropean journal of clinical pharmacology2015
A robust estimation of infliximab pharmacokinetic parameters in Crohn's disease.
Article in European journal of clinical pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Multi-model averaging improves the performance of model-guided infliximab dosing in patients with inflammatory bowel diseases.CPT: pharmacometrics & systems pharmacology · 2022Trial
- Connecting the Dots Between Pharmacokinetics, Inflammatory Biomarkers, and Mucosal Healing in Patients on Infliximab with Inflammatory Bowel Disease.Pharmaceutics · 2026Article
- Article
- Model-Informed Precision Dosing of Infliximab in Korean Inflammatory Bowel Disease Patients: External Validation of Population Pharmacokinetic Models.CPT: pharmacometrics & systems pharmacology · 2025Article
- Impact of Obesity and Metabolic Syndrome on IBD Outcomes.Digestive diseases and sciences · 2024Review
- Infliximab Treatment Does Not Lead to Full TNF-α Inhibition: A Target-Mediated Drug Disposition Model.Clinical pharmacokinetics · 2022Article
- Infliximab Efficacy May Be Linked to Full TNF-α Blockade in Peripheral Compartment-A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) Model.Pharmaceutics · 2021Article
- External Model Performance Evaluation of Twelve Infliximab Population Pharmacokinetic Models in Patients with Inflammatory Bowel Disease.Pharmaceutics · 2021Article
- External Evaluation of Population Pharmacokinetic Models and Bayes-Based Dosing of Infliximab.Pharmaceutics · 2021Article
- Physiologically-Based Pharmacokinetic Modeling vs. Allometric Scaling for the Prediction of Infliximab Pharmacokinetics in Pediatric Patients.CPT: pharmacometrics & systems pharmacology · 2019Article
- Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans.Clinical pharmacokinetics · 2019Review
- Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis.Clinical pharmacokinetics · 2019Review
- Model-Based Therapeutic Drug Monitoring of Infliximab Using a Single Serum Trough Concentration.Clinical pharmacokinetics · 2018Article
- Article
- Obesity in inflammatory bowel disease: A review of its role in the pathogenesis, natural history, and treatment of IBD.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationReview
Corrections and comments
- Comment on
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
26369535What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.